Vitro Diagnostics Inc. owns various U.S. patents for production of the fertility drug FSH, immortalization of cells, and adult stem cells. The company recently announced the newest addition to its current product lineup, a new serum-free stem cell growth medium.

According to the press release, the new product is a serum-free and animal component-free medium. The product is optimized for human stem-cell growth, and eliminates the risk of exposure to contamination from serum or animal components. Adult stem cells are usually derived from bone marrow, umbilical cord blood, or peripheral blood, which then must be purified to maximize therapeutic benefits. Vitro’s new serum-free stem cell growth medium reduces differentiation and harmful contamination.

Running under the banner, “Harnessing the Power of Cells,” Vitro continues to improve and improve its pipeline of patented adult stem cells and patent-pending technology for stem cell therapy of cancer. Today’s announcement is in line with the company’s long-term goals.

Dr. Joe Nieusma, a senior toxicologist and member of Vitro’s SAB, said the company is moving forward as one of the only stem-cell companies to offer several types of cell growth media.

“We are excited about all the new Vitro products that are moving rapidly into our pipeline. The newest and recently issued patent affords Vitro an exclusive proprietary position for a new cellular therapy to treat type I diabetes. Vitro’s new medium for human stem cells adds an important element to our other products: the culture of human stem cells under completely defined conditions necessary for rigorous FDA scrutiny of human clinical trials,” Dr. Nieusma stated in the press release. “Vitro is now one of the only stem cell companies to offer three types of stem cell growth media: low-serum, humanized and now serum-free, animal component-free and defined medium.”